Go to AAD Home
Donate For AAD Members Search

Go to AAD Home

Submit your iPLEDGE story

On December 13, a new platform was launched by isotretinoin manufacturers to support iPLEDGE, a risk management program required by the FDA to prevent exposure to the drug during pregnancy. Since then, patients, physicians, and pharmacists have faced considerable challenges getting into the platform to complete the prescribing process and patients risk losing access to the drug unless a workaround is found.

The American Academy of Dermatology Association is advocating vigorously with the FDA and drug manufacturers to find a solution. We’d like to hear from patients about the impact this is having on your care and what loss of your treatment will mean for you. General information will be shared with stakeholders, to help us restore access to treatment while maintaining patient safety. No personal information about you is being collected or shared.

Fill out my online form.